New data released Saturday at the 2021 European Society of Medical Oncology conference is garnering excitement for those seeking to battle some of the most challenging forms of breast cancer.
Researchers found using the antibody conjugate drug ENHERTU to treat currently incurable HER-2-positive breast cancer was significantly more successful at reducing tumor size and keeping the patient alive longer without progression of disease than the current standard of care TDM1.
"The outcome of this trial is very clinically meaningful for HER-2-positive breast cancer patients," Dr. Sara Tolaney, Chief, Division of Breast Oncology, Dana-Farber Cancer Institute, who was part of the research team, told ABC News. She predicted that"this potent antibody drug ... will dramatically change the treatment for HER-2 positive breast cancer.
This resulted in the phase 3 trial, which included approximately 500 patients over the age of 18 in 15 countries across Asia, Europe, North America, Oceania and South America. Half were treated with ENHERTU, half with TDM1. This trial by AstraZeneca and Daiichi Sankyo is the first global head-to-head randomized clinical trial for HER-2-positive breast cancer.
"With the remarkable results of this study, ENHERTU might become the new standard of care treatment for patients with HER-2-positive metastatic breast cancer following standard chemotherapy," Verma added.Pictured is a hand out image of a vial and packaging of ENHERTU, an antibody medication from AstraZeneca that when combined with chemotherapy is showing to extend the life of people with HER-2 positive breast cancer.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Prince Andrew Debuted a New Lawyer and a New Defense Strategy—Will It Work?In court this week, Andrew’s new Hollywood lawyer claimed the royal hadn’t been properly served and brought up a reason why he thinks the entire suit is baseless.
Lire la suite »
Democrats' Stumble on Drug Prices Shows Power of IndustryHouse Democrats writing the health provisions of their big social spending bill aimed high: new coverage for poor Americans without insurance; extra subsidies for people who buy their own coverage; and new dental, hearing and vision benefits for older Americans through Medicare. To pay for those, they also aimed high when it came to lowering drug prices. A measure that would link the prices of certain prescription drugs to those paid overseas was devised to save the government enough money to of
Lire la suite »
Prescription drug costs pose a stumbling block for Democrats on spending billThe package is full of contentious issues, but President Joe Biden's proposal to allow Medicare to negotiate drug prices has already hit opposition among some Democrats, and is the target of extensive lobbying efforts by pharmaceutical companies.
Lire la suite »
Prescription drug costs pose a stumbling block for Democrats on spending billDemocrats in Congress face difficult decisions about how to tackle prescription drug costs for seniors after it emerged as a sticking point between lawmakers.
Lire la suite »
States warn of COVID-19 antibody drug shortageOfficials in several states are voicing concern over shortages of monoclonal antibody drugs used to treat COVID-19 patients.
Lire la suite »
Kin of Philippines 'drug war victims' hope for justice as ICC approves probeFamilies of people killed in the Philippines' war on drugs are hopeful that a formal investigation into possible crimes against humanity approved by judges from the International Criminal Court earlier this week will result in justice for the victims.
Lire la suite »